# US 8,278,099 B1 · Monoclonal antibody to human thrombopoietin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,099 B1
- Document ID: US8278099B1
- Status: Granted
- Kind: B1
- Application number: 08/433,767
- Filed: 1995-05-03
- Granted: 2012-10-02
- Earliest claimed: 1994-02-15
- Assignees: Genentech, Inc.
- Inventors: Dan L. Eaton; Frederic J. de Sauvage
- Web page: https://patentgrep.com/patent/US8278099B1

## CPC

- C07K 14/524: {Thrombopoietin, i.e. C-MPL ligand}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Isolated thrombopoietin (TPO), isolated DNA encoding TPO, and recombinant or synthetic methods of preparing and purifying TPO are disclosed. Various forms of TPO are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.

## Claims

### Claim 1

A monoclonal antibody that is capable of binding an isolated substantially homogeneous mpl ligand, the mpl ligand consisting of amino acid residues 1 to X of FIG. 1 (SEQ ID NO:1) where X is selected from the group 153, 155, 164, 174, 191, 205, 207, 217, 229, 245, and 332.

### Claim 2 (depends on 1)

A hybridoma cell line producing the antibody of claim 1.
